According to Wells Fargo Advisors, "BAX: OMCL Would Be An Excellent Fit ... OMCL would bring better IT integration and an expanded set of hospital relationships as Baxter launches a new infusion pump next year. OMCL might also be able to finally realize its vision of a stronger international business (9% of total revenue) with the help of Baxter’s infrastructure. The pandemic pressured OMCL’s original 13% revenue growth target for 2020 down to a 2% revenue decline. However, management indicated bookings surged so much in Q3 the company was able to reinstate its original 9% bookings growth guidance for 2020 and gave a 2021 revenue outlook of 17% growth (13% organic). So, fundamentals seem solid."
Comment
⋅
BAX is back to the bottom of its short-term trading range. Its TipRanks Smart Score is a high neutral. The TipRanks Smart Score is quantitatively derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors.